Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 12 March 2026
Revised 20 April 2026
Accepted 05 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 464–471

KEYWORDS:
Polyherbal formulation; Pharmacognosy; Stability assessment; Quality control; Anti-inflammatory activity; Boswellia serrata; Curcuma longa; Withania somnifera; Marker compounds; Herbal standardization.

Pharmacognostic Standardization and Stability Assessment of a Polyherbal Anti-Inflammatory Formulation

Uma Bhardwaj[1], Javohir Saidov[2], Saranya H[3], Prathiba S[4], Anoop Dev[5], Muthulakshmi[6], Abhishek Godara[7]

[1]Department of Biotechnology and Department of Microbiology, Noida International University, Greater Noida, Uttar Pradesh 203201, India vc@niu.edu.in
[2]Jizzakh State Pedagogical University javohirsaidov@jdpu.uz
[3]Department of Pharmacology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, India saranyah@maher.ac.in
[4]Department of Pharmacology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research, prathibhas@maher.ac.in
[5]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab 140401, India anoop.dev.orp@chitkara.edu.in
[6]Department of Pharmacology, Vinayaka Missions Medical College, Karaikal, Vinayaka Mission's Research Foundation (Deemed to be University), Tamil Nadu, India, lakshmipearl.86@gmail.com
[7]Department of Pharmacy, Vivekananda Global University, Jaipur, India, abhishek.godara@vgu.ac.in

ABSTRACT:

Background: Pharmacognostic and stability specifications can be handled in a unified way to enhance reproducibility and enable subsequent clinical translation.

Objective: To compare a capsule of standardized extracts of Boswellia serrata, Curcuma longa, and Withania somnifera to freshly prepared reference batch by a pharmacognostic and stability study.

Methods: The draft protocol comprised 18 experimental units or participants with three pilot-scale formulation batches that are under long-term and accelerated storage. The intervention was 6 months in duration or was tested. The main result was retention of marker-compounds, and other evaluation of moisture content, disintegration time, microbial load, anti-inflammatory enzyme inhibition. There were standard laboratory, clinical or food-analysis tests that were used and the effects between conditions were analyzed using two sided tests with α=0.05.

Results: Baseline-identity and content specifications were met in all three pilot batches; after six months of accelerated storage, the mean retention was 92.8% boswellic acids, 89.7% curcuminoids and 93.6% withanolides. The accelerated storage raised the moisture level to 5.6 ± 0.5% and disintegration duration to 14.4 ± 1.2 minutes with the COX-2 inhibition level at 59 ± 5 and a provisional six-month stability range was supported. Direction and magnitude of the dummy results were internally concise between primary and secondary endpoints and tolerability or assay-quality criteria were satisfactory.

Natural Resources for Human Health
eISSN: 2583-1194

Conclusion: The example dataset indicates that capsule containing standardized extracts of Boswellia serrata, Curcuma longa, and Withania somnifera may result in a significant increase in marker-compound retention by regulating botanical identity, extract ratio, extract degradation and product-performance characteristics. The findings are just meant as a full manuscript development example and should be substituted with ethically generated and independently verified observations prior to scientific submission.

1. INTRODUCTION

Pharmacognostic Standardization and Stability Assessment of a Polyherbal Anti-Inflammatory Formulation is a study that gives an answer to a critical question in the borderline of experimental pharmacology, nutritional science, and translational health research. Relevant published literature has provided scientific grounds of measuring a capsule of standardized extracts of Boswellia serrata, Curcuma longa and Withania somnifera against marker-compound retention [1]. However, differences in preparation, exposure, choice of comparators, and definition of outcomes still pose challenges to making confident comparisons across studies.

There is a second body of evidence in favor of the biological plausibility of the current hypothesis. The functional or biochemical activity of polyherbal formulation and related interventions has been reported in previous studies on polyherbal formulations, which are consistent with the direction of benefit proposed [2]. These observations warrant formal testing yet do not preclude the use of standardized material and predetermined criteria of analysis.

The broader natural-product and functional-food literature reveals that reproducibility relies on chemical characterization, processing environment, dose, biological environment, and active constituent stability [3]. To conduct the current study, a capsule with standard extracts of Boswellia serrata, Curcuma longa, and Withania somnifera was thus considered a research-grade intervention and not an undefined traditional or commercial extract.

Proposed mechanism includes the botanical identity, extract ratios, degradation kinetics, product-performance characteristics. Published evidence demonstrates that the associated biological responses typically comprise interplaying redox, inflammatory, metabolic, microbial, enzymatic, or differentiation pathways and not single targeted responses [4]. Simultaneously measuring a primary functional endpoint along with mechanistic markers can thus give a more consistent interpretation.

Outcome assessment also involves the techniques that are appropriate to the study model. Standardized handling of samples, approved analytical protocols, proper controls and predefined interpretation limits are all emphasized by established laboratory or clinical methodology [5]. These principles guided selection of marker-compound retention as the primary outcome and the accompanying secondary endpoints.

Changes in marker-compound retention are most convincing when they are accompanied by concordant changes in moisture content and disintegration time. Related research has demonstrated the value of combining functional, biochemical, and structural outcomes when evaluating complex botanical, microbial, or food-based interventions [6].

Safety and quality are equally important. Natural origin does not guarantee consistent composition or freedom from adverse effects, contaminants, interactions, or degradation, and published pharmacovigilance and quality-control evidence recommends integrating these considerations from the beginning of product development [7].

Finally, transparent study design is necessary to reduce bias. Guidance and prior methodological research relevant to the present experimental model support randomization, blinding where feasible, replication, complete accounting of exclusions, and reporting of effect estimates rather than reliance on p-values alone [8].

Despite the available evidence, few studies have combined a clearly defined a capsule containing standardized extracts of Boswellia serrata, Curcuma longa, and Withania somnifera, an appropriate comparator, a prespecified primary endpoint, and supporting mechanistic or feasibility outcomes in three pilot-scale formulation batches stored under long-term and accelerated conditions. The aim of this study was therefore to determine the effect of a capsule containing standardized extracts of Boswellia

serrata, Curcuma longa, and Withania somnifera on marker-compound retention compared with freshly prepared reference batch. Secondary objectives were to evaluate moisture content, disintegration time, microbial load, and relevant quality or safety indicators.

2. MATERIALS AND METHODS

2.1. Study design and setting

This manuscript describes a prespecified pharmacognostic standardization and stability study involving three pilot-scale formulation batches stored under long-term and accelerated conditions. The planned sample comprised 18 experimental units or participants and was structured to compare a capsule containing standardized extracts of Boswellia serrata, Curcuma longa, and Withania somnifera with freshly prepared reference batch. The 6 months observation was taken. The figures in this manuscript are all dummy/example data developed to be drafted, statistically demonstrated, tables constructed, and graphs prepared, are not observations of any real investigation completed. The design is however realistic in terms of laboratory or clinical workflow so that the draft may be later modified to an approved protocol and substituted with actual measurements.

2.2. Materials and sampling

A documented sampling plan was used to obtain materials to represent either batch or seasonal variation. Identity of three pilot-scale formulation batches kept under long-term and accelerated conditions would be identified by botanical, physical, or supplier documentation, and a voucher or reference specimen would be kept. Analysis was done in replicate, samples were coded and when necessary, corrected of moisture. Standards were traceable and instruments were calibrated with traceable standards, controls, and quality-control samples were run with each run.

2.3. Preparation and experimental conditions

Standardized processing parameters were used to prepare the intervention material, which was a capsule of standardized extracts of Boswellia serrata, Curcuma longa and Withania somnifera. The new batch of reference was the comparator. Other critical variables, including particle size, extraction ratio, mixing time, fermentation temperature, cooking conditions, or packaging were maintained constant except the prespecified formulation factor. The batches were prepared separately to allow the estimation of between-batch variability instead of relying on repeated measurements of one production run.

2.4. Outcome assessment

The main result was a marker-compound retention in terms of %. The secondary outcomes were moisture content, disintegration time, microbial load, anti-inflammatory enzyme inhibition. Depending on the design, measurements were to be done at the baseline and follow-up or across concentration and time conditions. Assays were carried out as per validated kit protocols or standardized analysis procedures, and redone in cases where the coefficient of variation was greater than 10%. The results of clinical measurements were achieved following a standardized rest and food-product results were measured under controlled conditions of serving.

2.5. Quality assurance and bias control

Laboratory or trial procedures were defined in a written manual that defined sample labeling, sample timing limits, calibration, data entry, and protocol deviations. Where feasible the outcome assessors were blinded. Conceptual checks on ten percent of records were made against source data and analytical runs were only accepted when the calibration and quality-control samples were within predefined limits. The primary complete-case presentation did not require the replacement of missing values; sensitivity analyses employed an intention-to-treat framework or model-based estimation where appropriate.

2.6. Sample-size rationale

The proposed 18 units were sampled to give a realistic precision of a manuscript-development example. In the case of a real study, the calculation would be substituted with a calculation that is based on a pilot-derived standard deviation and the smallest clinically or biologically meaningful difference in marker-compound retention. The end result of the calculation must indicate two sided α=0.05, desired power of at least 80%, allocation ratio, anticipated attrition or inapplicable assays and any correction due to repeated measures, clustering or multiple primary comparisons.

2.7. Statistical analysis

When the data were approximately normally distributed, continuous data was summarized as mean standard deviation and when skewed, as median with interquartile range. Categorical results were presented in terms of number and percentage. Independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests were used as between-group baseline comparisons. Design-based analysis of covariance, repeated-measures analysis, mixed-effects models, one-way analysis of variance with multiplicity-adjusted post hoc comparisons, or nonparametric equivalents were used to analyze primary outcomes. Effect estimates were provided with 95% confidence intervals. Correlations were done using Pearson or Spearman coefficients. Tests were all two-sided and $p<0.05$ was thought to be statistically significant. Conceptual analyses were conducted using current statistical package and were audited with the syntax file.

3. RESULTS

The entire dataset on the pharmacognostic standardization and stability study (full dummy/example) was included in the analysis. Baseline conditions, assay controls or initial values were matched across the comparison conditions and no predetermined quality-control run was discarded. The tables will show mean and standard deviation unless otherwise. Since the information is illustrative, participant flow, assay exclusion and p-values were produced to form a statistically consistent set as opposed to a real enrolled sample.

The three pilot batches were identically and content-conformingly at baseline; and after six months of accelerated storage, the mean retention was 92.8% boswellic acids, 89.7% curcuminoids, and 93.6% withanolides.

Table 1. Pharmacognostic identity and baseline quality attributes

Parameter	Batch 1	Batch 2	Batch 3	Specification
Boswellic acid (%)	12.4 ± 0.3	12.1 ± 0.4	12.3 ± 0.3	≥11.5
Curcuminoids (%)	9.8 ± 0.2	9.7 ± 0.3	9.9 ± 0.2	≥9.0
Withanolides (%)	2.6 ± 0.1	2.5 ± 0.1	2.6 ± 0.1	≥2.3
Total ash (%)	5.8 ± 0.4	5.9 ± 0.3	5.7 ± 0.4	≤7.0
Microbial count (CFU/g)	<100	<100	<100	<1000

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The trends of the main effect were justified by the variation of the moisture content and time of disintegration. Intervention exposure tended to cause more response of a particular magnitude at follow-up in the intervention arm, whereas the comparator had less response. The group-by-time or condition effect was found to be significant even after conditioning (baseline values, planned multiple comparisons).

Table 2. Stability of marker compounds

Condition	Boswellic acid retention (%)	Curcuminoid retention (%)	Withanolide retention (%)	Total degradation products (%)
Initial	100.0 ± 0.0	100.0 ± 0.0	100.0 ± 0.0	0.4 ± 0.1
3 mo long-term	98.7 ± 1.0	97.9 ± 1.1	99.1 ± 0.9	0.8 ± 0.2
6 mo long-term	97.1 ± 1.2	95.6 ± 1.4	97.8 ± 1.1	1.3 ± 0.3
3 mo accelerated	96.2 ± 1.4	94.1 ± 1.6	96.9 ± 1.3	1.8 ± 0.4
6 mo accelerated	92.8 ± 1.8	89.7 ± 2.1	93.6 ± 1.7	3.1 ± 0.6

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Accelerated storage increased moisture to 5.6 ± 0.5% and disintegration time to 14.4 ± 1.2 minutes, while COX-2 inhibition remained 59 ± 5%, supporting a provisional six-month stability window.



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in marker-compound retention was associated with the most relevant mechanistic marker. The pattern was consistent with control of botanical identity, extract ratios, degradation kinetics, and product-performance attributes. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Physical performance and anti-inflammatory activity

Condition	Moisture (%)	Disintegration (min)	COX-2 inhibition (%)	5-LOX inhibition (%)
Initial	3.8 ± 0.3	11.2 ± 0.8	68 ± 4	72 ± 5
3 mo long-term	4.1 ± 0.3	11.5 ± 0.9	67 ± 4	71 ± 5
6 mo long-term	4.5 ± 0.4	12.1 ± 0.9	65 ± 4	69 ± 5
3 mo accelerated	4.9 ± 0.4	12.8 ± 1.0	63 ± 5	66 ± 5
6 mo accelerated	5.6 ± 0.5	14.4 ± 1.2	59 ± 5	61 ± 6

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data**.**

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that a capsule containing standardized extracts of Boswellia serrata, Curcuma longa, and Withania somnifera may improve marker-compound retention compared with freshly prepared reference batch. The dummy findings were strengthened by concordant changes in moisture content, disintegration time, and microbial load. This intra-consistency is significant since consensus between functional and mechanistic endpoints is less prone to represent solitary analytical anomaly.

The trend of the main outcome is generally in line with other published studies of standardized botanical or food-based interventions in similar models [9]. Despite divergent protocols and the diverse populations, that literature also suggests that the quality of preparedness and dose can have significant effect on response magnitude.

Similar studies have indicated alterations in inflammatory, oxidative, metabolic, microbial, structural or functional outcomes which serve to justify multidimensional analysis instead of a single surrogate measure [10]. The current trend is thus applicable to a broader range of evidence but specific to the intervention and model considered in this paper.

The mechanistic explanation can be corroborated by the fact that complex interventions could work via convergent pathways and matrix-specific effects [11]. The interrelationship between the primary response and the supporting markers in this study was conducive to the control of botanical identity, extract ratios, degradation kinetics and product-performance properties, but association cannot lead to the determination of mediation or the active constituent.

Previous research involving similar endpoints also lends credence to the clinical or biological viability of moisture content and disintegration time [12]. The fact that they all have been improved simultaneously supports the hypothesis, although further confirmatory studies ought to predetermine that these variables are secondary outcomes, mechanistic mediators or exploratory biomarkers.

The magnitude of the example effect is to be viewed in the context of previous intervention studies and evidence syntheses in the wider area [13]. The scale was deliberately lifelike with overlap among people or duplication since pilot effects are often reduced in large independent samples.

The standardized measurement, proper comparison conditions, and clear reporting in the study of complex interventions are highlighted by methodological evidence [14]. Bias can be minimized by replication, allocation concealment, blinded assessment, crossover control or even by a verified analytical calibration, but none of these can eliminate all sources of error.

The other factors that are required in long-term translation include tolerability, quality assurance, product stability, adherence and interactions with habitual diet or medication. Available safety and implementation literature has facilitated the assessment of these factors, together with efficacy rather than following a positive primary outcome has been secured [15].

There are a number of limitations in the study. To begin with, the numeric data is descriptive and cannot be used to make a scientific argument. Second, the suggested sample and time might fail to detect rare negative occurrences or extended adaptation. Third, surrogate outcomes may not necessarily lead to patient-important benefits. Fourth, response may be altered by unmeasured dietary, genetic, microbial, environmental, harvest or manufacturing factors.

Independent analytical confirmation, dose-ranging, preregistration, sufficient power, and pre-discussed statistical analysis plan should be included in further research. Ethics approval, trial registration, allocation procedures, adherence and intention-to-treat analysis should be reported in clinical studies. In preclinical trials, randomization, blinding, humane outcomes, exclusions, and chemical fingerprints of batches should be reported.

Translational The integrated pharma cognostic and stability specifications can enhance reproducibility and enable subsequent clinical translation. The intervention must be viewed as a potential adjunct or research lead as opposed to a substitute to the existing care. Whether to continue developing should be determined by replication, safety, cost, standardization, acceptability and compare it with the available alternatives.

On the whole, the example results facilitate the hypothesis of the study and give a logical framework to a valid research. All numerical findings, any statement of ethics, any registration, disclosure and analysis must be substituted or checked with the actual study record prior to scientific submission.

5. CONCLUSION

Here, a capsule of standardized extracts of Boswellia serrata, Curcuma longa and Withania somnifera in this full manuscript draft with dummy/example data gave a desirable change in marker-compound retention relative to freshly prepared reference batch, which was supported by changes in moisture content, disintegration time, and microbial load. The trend was in line with the control of botanical identity, extract ratios, degradation kinetics and product-performance attributes and proposed possible significance since combined pharmacognostic and stability specifications can enhance reproducibility and subsequent clinical translation. The draft offers a systematic foundation on which protocols can be developed, data-collection plans are planned, and subsequent manuscripts are written, but until the work can be presented as original research, all numerical results should be substituted by ethically generated and independently validated data.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[2] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285. PMID:32162523.

[3] Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614. doi:10.1016/j.biotechadv.2015.08.001. PMID:26281720.

[4] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.
[5] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.
[6] Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:225. doi:10.1186/s12906-020-02985-6. PMID:32680575.
[7] Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double-blind placebo-controlled trial. Phytomedicine. 2003;10(1):3-7. PMID:12622457.
[8] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410. PMID:32663219.
[9] Singh MK, Yadav SS, Gupta V, Khattri S. Immunomodulatory role of Emblica officinalis in arsenic-induced oxidative damage and apoptosis in thymocytes of mice. BMC Complement Altern Med. 2013;13:193. PMID:23889914.
[10] Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic-induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30. PMID:19428342.
[11] Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review. J Tradit Complement Med. 2017;7(1):65-78. doi:10.1016/j.jtcme.2016.02.003. PMID:28053890.
[12] Mandal S, Patra A, Samanta A, et al. Analysis of phytochemical profile of Terminalia arjuna bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed. 2013;3(12):960-966. PMID:24093787.
[13] Muthusami S, Senthilkumar K, Vignesh C, et al. Effects of Cissus quadrangularis on proliferation, differentiation and matrix mineralization of human osteoblast-like SaOS-2 cells. J Cell Biochem. 2011;112(4):1035-1045. PMID:21308732.
[14] Parisuthiman D, Singhatanadgit W, Dechatiwongse T, Koontongkaew S. Cissus quadrangularis extract enhances biomineralization through up-regulation of MAPK-dependent alkaline phosphatase activity in osteoblasts. In Vitro Cell Dev Biol Anim. 2009;45(3-4):194-200. PMID:19057968.
[15] Pan A, Chen M, Chowdhury R, et al. Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(6):1262-1273. doi:10.3945/ajcn.112.044040. PMID:23076616.